PMID- 22780580
OWN - NLM
STAT- MEDLINE
DCOM- 20130304
LR  - 20171116
IS  - 1528-1167 (Electronic)
IS  - 0013-9580 (Linking)
VI  - 54
IP  - 1
DP  - 2013 Jan
TI  - Dramatic weight loss with rufinamide.
PG  - e5-8
LID - 10.1111/j.1528-1167.2012.03579.x [doi]
AB  - Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy 
      in the treatment of Lennox-Gastaut syndrome. Treatment-emergent adverse events 
      (AEs) have consisted mainly of drowsiness, irritability, vomiting, and loss of 
      appetite. RUF is considered as a "weight-neutral" drug. We found clinically 
      significant weight loss in 7 of 15 consecutive adult patients (47%; 3 male, 4 
      female, aged 18-31 years) treated with RUF as add-on therapy (800-2,400 mg/day: 
      23.5-57.1 mg/kg/day). The body mass index (BMI) decreased by 7.3-18.7%. Two 
      patients were obese class I before RUF. Five patients (71%) were underweight 
      before RUF (mild in one case, moderate in two cases, and severe in two cases). 
      Four of these patients stopped RUF because of this adverse effect. RUF was 
      recommenced in two patients using a lower and slower dosing strategy; one patient 
      showed improvement in seizure control and no weight loss but RUF was re-stopped 
      in the second patient because of continued weight loss. Despite of weight loss, 
      RUF was continued in two other patients because it reduced seizure activity. We 
      primarily related weight loss to reduced food intake, that is, loss of appetite 
      and nausea, although in two patients no obvious loss of appetite was reported. 
      RUF can cause clinically significant weight loss in adult patients, even at low 
      dose. This AE can affect patients who are already underweight. There is a 
      possibility that lower starting doses and slower escalation might minimize weight 
      loss, but further information is required to determine whether this is the case.
CI  - Wiley Periodicals, Inc. (c) 2012 International League Against Epilepsy.
FAU - Mourand, Isabelle
AU  - Mourand I
AD  - Department of Neurology, Gui de Chauliac Hospital, Montpellier, France. 
      i-mourand@chu-montpellier.fr
FAU - Crespel, Arielle
AU  - Crespel A
FAU - Gelisse, Philippe
AU  - Gelisse P
LA  - eng
PT  - Journal Article
DEP - 20120710
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Anticonvulsants)
RN  - 0 (Triazoles)
RN  - WFW942PR79 (rufinamide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/*adverse effects/therapeutic use
MH  - Body Mass Index
MH  - Epilepsy/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Triazoles/*adverse effects/therapeutic use
MH  - Weight Loss/*drug effects
MH  - Young Adult
EDAT- 2012/07/12 06:00
MHDA- 2013/03/05 06:00
CRDT- 2012/07/12 06:00
PHST- 2012/07/12 06:00 [entrez]
PHST- 2012/07/12 06:00 [pubmed]
PHST- 2013/03/05 06:00 [medline]
AID - 10.1111/j.1528-1167.2012.03579.x [doi]
PST - ppublish
SO  - Epilepsia. 2013 Jan;54(1):e5-8. doi: 10.1111/j.1528-1167.2012.03579.x. Epub 2012 
      Jul 10.